Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vascular diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,302 result(s) found for: Vascular diseases. Displaying page 6 of 66.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2021-001633-40 Sponsor Protocol Number: ESRA Start Date*: 2022-03-07
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial Hypertension Doubleblind, randomized, multicentre, multinational, pla...
    Medical condition: early pulmonary vascular disease, defined as either a) mean pulmonary arterial pressure (mPAP) ≥25 mmHg with pulmonary vascular resistance (PVR) ≥2 to <3 WU and pulmonary arterial wedge pressure (P...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037455 Pulmonary vascular disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001477-33 Sponsor Protocol Number: 071102 Start Date*: 2016-12-01
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleed...
    Medical condition: Hereditary severe von Willebrand Disease in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Completed) ES (Trial now transitioned) FR (Trial now transitioned) DE (Completed) NL (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-004906-88 Sponsor Protocol Number: NL69395.042.19 Start Date*: 2020-04-24
    Sponsor Name:University Medical Center Groningen
    Full Title: Placebo-controlled double-blind randomized controlled trial investigating vitamin K supplementation on vascular calcification propensity in vitamin K deficient renal transplant recipients
    Medical condition: Vitamin K deficiency is highly prevalent among renal transplant recipients, promotes vascular calcification, and is associated with an increased risk of cardiovascular disease. Supplementation of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001784-27 Sponsor Protocol Number: 2018/0419/HP Start Date*: 2022-10-11
    Sponsor Name:Direction de la Recherche Clinique et de l'Innovation - CHU de Rouen
    Full Title: Tolerance of intra-articular injection of autologous stromal vascular fraction for the treatment of rhizarthrosis
    Medical condition: Adults with a rhizarthrosis stage DELL 1 to 3
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004043-35 Sponsor Protocol Number: sugar1 Start Date*: 2007-02-16
    Sponsor Name:
    Full Title: Effects of Sulodexide on damaged endothelial Glycocalyx in pAtients with Diabetes Mellitus type II; Reversing damage.
    Medical condition: diabetes mellitus type II with and without microalbuminuria, damaged glycocalyx
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006749-42 Sponsor Protocol Number: 31350 Start Date*: 2009-01-09
    Sponsor Name:University of Nottingham
    Full Title: Safety and efficacy of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke or TIA: a randomised controlled trial
    Medical condition: Ischaemic stroke and TIA (transient ischaemic attack)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    14.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001817-20 Sponsor Protocol Number: NL73805.100.20 Start Date*: 2021-05-07
    Sponsor Name:St. Antonius Hospital Nieuwegein, The Netherlands
    Full Title: Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation
    Medical condition: Thromboembolic, bleeding and vascular complications after transcatheter aortic valve implantation in patients using oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004626-17 Sponsor Protocol Number: 1101/08 Start Date*: 2009-03-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Anti-inflammatory and Anti-platelet effect of Clopidogrel and Aspirin vs Aspirin alone in Symptomatic Polyvascular disease and in patients with multiple recurrent cardiovascular events.
    Medical condition: Polyvascular disease and in patients with multiple recurrent cardiovascular events.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10032377 Other peripheral vascular disease LLT
    9.1 10028600 Myocardial ischaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004748-23 Sponsor Protocol Number: 2011080362 Start Date*: 2011-12-05
    Sponsor Name:Neurologisk Afdeling
    Full Title: Risk of apoplexia cerebri in clopidogrel non-responders.
    Medical condition: Apoplexia cerebri
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001703-32 Sponsor Protocol Number: VASE Start Date*: 2015-11-09
    Sponsor Name:Cliniques Universitaires Saint-Luc (CUSL)
    Full Title: Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care
    Medical condition: Complex vascular anomalies causing debilitating functional and esthetic impairment that are resistant to standard care
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10047047 Vascular anomalies congenital NEC HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Ongoing) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001256-20 Sponsor Protocol Number: ITI 101724 Start Date*: 2005-11-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 375 ...
    Medical condition: Non-valvular Atrial Fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) EE (Completed) HU (Completed) DK (Completed) LV (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002225-19 Sponsor Protocol Number: FE001 Start Date*: 2016-01-18
    Sponsor Name:Diagnostic Centre of Pécs
    Full Title: Ferumoxytol as an MR contrast agent in CNS and head & neck tumors, intracranial and peripheral vascular disease
    Medical condition: Feraheme will be tested as an MRI contrast agent in the diseases of the central nervous system, in head and neck tumors and peripheral vascular diseases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006056-37 Sponsor Protocol Number: 1160.143 Start Date*: 2013-09-05
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi...
    Medical condition: MINS (myocardial injury after noncardiac surgery)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10066592 Post procedural myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-003653-15 Sponsor Protocol Number: AC-055G202 Start Date*: 2017-09-12
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascu...
    Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-001678-25 Sponsor Protocol Number: 138/06 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for vascular retinopathy a interventional study.
    Medical condition: vascular retinopathy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038923 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004344-28 Sponsor Protocol Number: WIL-33 Start Date*: 2022-08-15
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: CLINICAL STUDY TO INVESTIGATE THE EFFICACY, PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WILATE IN SEVERE VON WILLEBRAND DISEASE PATIENTS UNDER THE AGE OF 6 YEARS
    Medical condition: Routine prophylaxis in children under the age of 6 years with severe VWD
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001523-31 Sponsor Protocol Number: U1111-1181-4107 Start Date*: 2017-01-30
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebo-controlled, double-blind, parallel clinical PET/CT trial
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005784-24 Sponsor Protocol Number: MEIXO-VALV-001 Start Date*: 2012-06-14
    Sponsor Name:Andres Iñiguez Romo
    Full Title: Dual antiplatelet therapy versus oral anticoagulation for a short time to prevent cerebral embolism after percutaneous aortic valve implantation. Multicenter randomized clinical trial.
    Medical condition: Evaluate the efficacy of dual antiplatelet therapy versus oral anticoagulation for primary prevention of cerebral thromboembolism at three months after percutaneous aortic valve implantation (TAVI).
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001666-10 Sponsor Protocol Number: 20140415 Start Date*: 2014-06-24
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Local delivery of CER-001 in advanced plaques Proof-of-concept for apoA-1 as initiator of reverse cholesterol transport (LOCATION)
    Medical condition: Atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 07:35:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA